NeoVista, Inc., is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50.
The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system
